参考文献/References:
[1] Watanabe J,Iwazu Y,Kotani K. Pulse wave velocity,carotid intima media thickness and flow-mediated dilation in Takayasu arteritis: a systematic review[J]. Arch Med Sci Atheroscler Dis,2021,16(6):e79-e84.
[2] Watanabe R,Berry GJ,Liang DH,et al. Cellular signaling pathways in medium and large vessel vasculitis[J]. Front Immunol,2020,25(11):587089.
[3] Hadjadj J,Canaud G,Mirault T,et al. mTOR pathway is activated in endothelial cells from patients with Takayasu arteritis and is modulated by serum immunoglobulin G[J]. Rheumatology (Oxford),2018,57(6):1011-1020.
[4] Maciejewski-Duval A,Comarmond C,Leroyer A,et al. mTOR pathway activation in large vessel vasculitis[J]. J Autoimmun,2018,94:99-109.
[5] Hatri A,Guermaz R,Laroche JP,et al. Takayasu’s arteritis and atherosclerosis[J]. J Med Vasc,2019,44(5):311-317.
[6] Hosseini H,Yi L,Kanellakis P,et al. Anti-TIM-1 monoclonal antibody (RMT1-10) attenuates atherosclerosis by expanding IgM-producing B1a cells[J]. J Am Heart Assoc,2018,7(13):e008447.
[7] Srikakulapu P,McNamara CA. B cells and atherosclerosis[J]. Am J Physiol Heart Circ Physiol,2017,312(5):H1060-H1067.
[8] Tay C,Kanellakis P,Hosseini H,et al. B Cell and CD4 T cell interactions promote development of atherosclerosis[J]. Front Immunol,2020,10:3046.
[9] Ou HX,Guo BB,Liu Q,et al. Regulatory T cells as a new therapeutic target for atherosclerosis[J]. Acta Pharmacol Sin,2018,39(8):1249-1258.
[10] Clement M,Galy A,Bruneval P,et al. Tertiary lymphoid organs in Takayasu arteritis[J]. Front Immunol,2016,22(7):158.
[11] Yin C,Mohanta SK,Srikakulapu P,et al. Artery tertiary lymphoid organs: powerhouses of atherosclerosis immunity[J]. Front Immunol,2016,10(7):387.
[12] Clement M,Guedj K,Andreata F,et al. Control of the T follicular helper-germinal center B-cell axis by CD8? regulatory T cells limits atherosclerosis and tertiary lymphoid organ development[J]. Circulation,2015,131(6):560-570.
[13] Michalska-Jakubus MM,Rusek M,Kowal M,et al. Anti-endothelial cell antibodies are associated with apoptotic endothelial microparticles,endothelial sloughing and decrease in angiogenic progenitors in systemic sclerosis[J]. Postepy Dermatol Alergol,2020,37(5):725-735.
[14] Masamune A,Saiki Y,Harigae H,et al. Identification of two major autoantigens negatively regulating endothelial activation in Takayasu arteritis[J]. Nat Commun,2020,11(1):1253.
[15] Li J,Sun F,Chen Z,et al. The clinical characteristics of Chinese Takayasu’s arteritis patients: a retrospective study of 411 patients over 24 years[J]. Arthritis Res Ther,2017,19(1):107.
[16] Qi Y,Yang L,Zhang H,et al. The presentation and management of hypertension in a large cohort of Takayasu arteritis[J]. Clin Rheumatol,2018,37(10):2781-2788.
[17] Grotenhuis HB,Aeschlimann FA,Hui W,et al. Increased arterial stiffness adversely affects left ventricular mechanics in patients with pediatric Takayasu arteritis from a toronto cohort[J]. J Clin Rheumatol,2019,25(4):171-175.
[18] Chen Y,Waqar AB,Yan H,et al. Renovascular hypertension aggravates atherosclerosis in cholesterol-fed rabbits[J]. J Vasc Res,2019,56(1):28-38.
[19] Chistiakov DA,Orekhov AN,Bobryshev YV. ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease[J]. Lab Invest,2016,96(7):708-718.
[20] Wang X,Chen B,Lv N,et al. Association of abnormal lipid spectrum with the disease activity of Takayasu arteritis[J]. Clin Rheumatol,2015,34(7):1243-1248.
[21] Reynoso-Villalpando GL,Sevillano-Collantes C,Valle Y,et al. ApoB/ApoA1 ratio and non-HDL-cholesterol/HDL-cholesterol ratio are associated to metabolic syndrome in patients with type 2 diabetes mellitus subjects and to ischemic cardiomyopathy in diabetic women[J]. Endocrinol Diabetes Nutr (Engl Ed),2019,66(8):502-511.
[22] Kattoor AJ,Kanuri SH,Mehta JL. Role of Ox-LDL and LOX-1 in atherogenesis[J]. Curr Med Chem,2019,26(9):1693-1700.
[23] Chen S,Luan H,He J,et al. The relationships of serum homocysteine levels and traditional lipid indicators with disease activity and coronary artery involvement in Takayasu arteritis[J]. Immunol Res,2020,68(6):405-413.
[24] Pan L,Du J,Chen D,et al. Takayasu arteritis with dyslipidemia increases risk of aneurysm[J]. Sci Rep,2019,9(1):14083.
[25]Alarcón GJC,Rodríguez SS,Mu?iz GO,et al. Vascular lesions in patient with Takayasu arteritis and massive elevated lipoprotein(a) levels[J]. Clin Investig Arterioscler,2017,29(2):98-102.
[26] Forbes CA,Quek RG,Deshpande S,et al. The relationship between Lp(a) and CVD outcomes: a systematic review[J]. Lipids Health Dis,2016,15:95.
[27] Vander VFM,Bekkering S,Kroon J,et al. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans[J]. Circulation,2016,134(8):611-624.
[28] Vavuranakis MA,Jones SR,Cardoso R,et al. The role of Lipoprotein(a) in cardiovascular disease: Current concepts and future perspectives[J]. Hellenic J Cardiol,2020,61(6):398-403.
[29] Tanaka N,Masuoka S,Kusunoki N,et al. Serum resistin level and progression of atherosclerosis during glucocorticoid therapy for systemic autoimmune diseases[J]. Metabolites,2016,6(3):28.
[30] Jeries H,Volkova N,Grajeda-Iglesias C,et al. Prednisone and its active metabolite prednisolone attenuate lipid accumulation in macrophages[J]. J Cardiovasc Pharmacol Ther,2020,25(2):174-186.
[31] Trusca VG,Fuior EV,Fenyo IM,et al. Differential action of glucocorticoids on apolipoprotein E gene expression in macrophages and hepatocytes[J]. PLoS One,2017,12(3):e0174078.
[32] Zielińska KA,Van ML,Opdenakker G,et al. Endothelial response to glucocorticoids in inflammatory diseases[J]. Front Immunol,2016,7:592.
[33] Ajeganova S ,Gustafsson T,Lindberg L,et al. Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls,but this progression is still promoted by dyslipidaemia,lower HDL levels,hypertension,history of lupus nephritis and a higher prednisolone usage in patients[J]. Lupus Sci Med,2020,7(1):e000362.
[34] Roubille C,Richer V,Starnino T,et al. The effects of tumour necrosis factor inhibitors,methotrexate,non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis,psoriasis and psoriatic arthritis: a systematic review and meta-analysis[J]. Ann Rheum Dis,2015,74(3):480-489.
[35] Al Maruf A,O’Brien PJ,Naserzadeh P,et al. Methotrexate induced mitochondrial injury and cytochrome c release in rat liver hepatocytes[J]. Drug Chem Toxicol,2018,41(1):51-61.
[36] Oberoi R,Vlacil AK,Schuett J,et al. Anti-tumor necrosis factor-α therapy increases plaque burden in a mouse model of experimental atherosclerosis[J]. Atherosclerosis,2018,277:80-89.
相似文献/References:
[1]房晨鹂,综述,汪汉,等.大动脉炎的心脏损害[J].心血管病学进展,2016,(2):180.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.022]
FANG Chenli,WANG Han.Cardiac Involvement in Takayasu Arteritis[J].Advances in Cardiovascular Diseases,2016,(2):180.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.022]
[2]程晓艺,寇秀玲,黄明刚,等.颈动脉斑块与冠状动脉粥样硬化相关性影像学分析[J].心血管病学进展,2019,(6):960.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.030]
CHENG Xiaoyi,KOU Xiuling,HUANG Minggang,et al.Imaging Analysis of Carotid Plaque and Coronary Artery Atherosclerosis[J].Advances in Cardiovascular Diseases,2019,(2):960.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.030]
[3]韩月 朱莉 宋桂仙.白介素-12家族在冠状动脉粥样硬化中的研究进展[J].心血管病学进展,2020,(5):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
HAN Yue,ZHU Li,SONG Guixian.Interleukin-12 Family in Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2020,(2):508.[doi:10.16806/j.cnki.issn.1004-3934.20.05.016]
[4]梁春晓 李爽 刘莹 余建群.不同区域的心包脂肪容积与心血管危险因素及冠状动脉粥样硬化的关系[J].心血管病学进展,2020,(8):873.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
LIANG Chunxiao,LI Shuang,LIU Ying,et al.Epicardial, Paracardial and Pericardial Fat Volume by CCTA: Relationship with Cardiovascular Risk Factors and Coronary Atherosclerosis[J].Advances in Cardiovascular Diseases,2020,(2):873.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.022]
[5]李爽 梁春晓 方鑫 刘莹 余建群.心包内脂肪容积对糖尿病及非糖尿病患者冠状动脉粥样硬化影响的CT评价[J].心血管病学进展,2020,(9):972.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.021]
LI Shuang,LIANG Chunxiao,FANG Xin,et al.Effect of Epicardial Adipose Tissue Volume by CCTA on Coronary Atherosclerosis in Patients with or without Type 2 Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(2):972.[doi:10.16806/j.cnki.issn.1004-3934.2020.09.021]
[6]谭思华 周晓莉.非酒精性脂肪肝与冠状动脉粥样硬化及炎症的研究进展[J].心血管病学进展,2023,(5):439.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.013]
TAN Sihua,ZHOU Xiaoli.Association of Non-Alcoholic Fatty Liver Disease with Coronary Atherosclerosis and Inflammation[J].Advances in Cardiovascular Diseases,2023,(2):439.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.013]
[7]韩冰 来春林.黑色素瘤缺乏因子2炎症小体在心血管疾病中的研究进展[J].心血管病学进展,2023,(11):986.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.007]
HAN Bing,LAI Chunlin.Absent In Melanoma 2 Inflammasome in Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2023,(2):986.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.007]